When tested in a murine model of T2D, one SIRT-6 inhibitor having a quinazolinedione scaffold, improved glucose tolerance and reduced plasma levels of insulin, triglycerides, and cholesterol [180]. The gene discussed is INS; the disease is type 2 diabetes mellitus.